This study aimed to assess whether blood-derived L1CAM+ EVs could serve as biomarkers of treatment response to rituximab (RTX) in patients with relapsing-remitting MS (RRMS). The gene discussed is L1CAM; the disease is relapsing-remitting multiple sclerosis.